NCT00411593View on ClinicalTrials.gov

Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Lung Cancer
Interventions
DRUG

Bevacizumab

15 g/kg by vein every 3 weeks on day 1 of each cycle.

DRUG

Bortezomib

"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER